Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey R Neilson

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
European Journal of Haematology|July 28, 2007
Prolonged remission of pure white cell aplasia (PWCA), in a patient with CLL, induced by rituximab and maintained by continuous oral cyclosporinGeothy Chakupurakal, Richard J A Murrin, Jeffrey R Neilson
International Journal of Colorectal Disease|March 26, 2009
A pathological disagreementRoss O C Elledge, Rokhsareh Khazaee-Farid, Jeffrey R Neilson, et al.
The Lancet. Oncology|May 4, 2023
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trialPeter Hillmen, Alexandra Pitchford, Adrian Bloor, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
European Journal of Haematology|July 28, 2007
Prolonged remission of pure white cell aplasia (PWCA), in a patient with CLL, induced by rituximab and maintained by continuous oral cyclosporinGeothy Chakupurakal, Richard J A Murrin, Jeffrey R Neilson
International Journal of Colorectal Disease|March 26, 2009
A pathological disagreementRoss O C Elledge, Rokhsareh Khazaee-Farid, Jeffrey R Neilson, et al.
The Lancet. Oncology|May 4, 2023
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trialPeter Hillmen, Alexandra Pitchford, Adrian Bloor, et al.
Pageof 1